The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Self-citationChronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Self-citationHeikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice
Heikkila, R. E., Hess, A., & Duvoisin, R. C. (1984) · Science · doi:10.1126/science.6610213 · Cited by 1,009
Oxy-radical toxicity in catecholamine neurons.
Cohen, G. (1984) · PubMed · Cited by 222
Site-Specific, Sustained Release of Drugs to the Brain
Bodor, N., Farag, H. H., & Brewster, M. E. (1981) · Science · doi:10.1126/science.7313698 · Cited by 181
Research works printed but not linked: 6
- Lyle, R. E., Nelson, D. A. & Anderson, P. S. Tetrahedron Lett. 553–557 (1962). · doi:10.1016/s0040-4039(00)76928-0
- Ward, D. P. et al. Drug Metab. Disposit. 10, 690–695 (1982).
- Jacobowitz, D. M., Burns, R. S., Chiueh, C. C. & Kopin, I. J. Psychopharmac. Bull. 20, 416–422 (1984).
- Swartzbek, R. A. Proc. 12th Br. Weed Control Conf. Vol. 2, 851–856 (1974).
- Cohen, G. Neurotoxicology 5, 77–82 (1984).
- Birkmeyer, W., Knoll, J., Riederer, P. & Youdim, M. B. H. Mod. Probl. Pharmacopsychiat. 19, 170–176 (1983). · doi:10.1159/000407513
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081564 · Cited by 1,408
Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263
Nicklas, W. J., Vyas, I., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,262
Protocol for the MPTP mouse model of Parkinson's disease
Jackson-Lewis, V., & Przedborski, S. (2007) · Nature Protocols · doi:10.1038/nprot.2006.342 · Cited by 1,111
Mitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S. R., & Chesselet, M.-F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 913
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Przedborski, S., Jackson-Lewis, V, Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
Liu, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90425-c · Cited by 594
Functional changes of the basal ganglia circuitry in Parkinson's disease
Blandini, F., Nappi, G., Tassorelli, C., & Martignoni, E. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00067-2 · Cited by 582
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists
Turski, L., Bressler, K., Jürgen Rettig, K., Löschmann, P.-A., & Wachtel, H. (1991) · Nature · doi:10.1038/349414a0 · Cited by 546
Przedborski, S., Jackson‐Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., & Akram, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00183.x · Cited by 507
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
Distinct Monoamine Oxidase A and B Populations in Primate Brain
Westlund, K. N., Denney, R. M., Kochersperger, L. M., Rose, R. M., & Abell, C. W. (1985) · Science · doi:10.1126/science.3875898 · Cited by 504
Invited Review Free radicals and the pathobiology of brain dopamine systems
Cadet, J. L., & Brannock, C. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00031-4 · Cited by 499
Przedborski, S., Kostic, V, Jackson-Lewis, V, Naini, A., Simonetti, S., Fahn, S., Carlson, E., Epstein, C., & Cadet, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01658.1992 · Cited by 456
Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438
Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B. H., Hars, V., & Marton, J. (1985) · Journal of Neural Transmission · doi:10.1007/bf01245973 · Cited by 436
Langston, J. W. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179006 · Cited by 424
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Subramaniam, S. R., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 347
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., & Gendelman, H. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400569101 · Cited by 321
Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP
Javitch, J. A., & Snyder, S. H. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90740-4 · Cited by 317
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308
Self-citationMPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
Gerlach, M., Riederer, P., Przuntek, H., & Youdim, M. B. H. (1991) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(91)90073-q · Cited by 307
Heikkila, R. E., Nicklas, W. J., Vyas, I., & Duvoisin, R. C. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90580-4 · Cited by 300
MPTP Toxicity: Implications for Research in Parkinson's Disease
Kopin, I. J., & Markey, S. P. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000501 · Cited by 295
Self-citationNeurochemical findings in the MPTP model of Parkinson's disease
Schmidt, N., & Ferger, B. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100004 · Cited by 290
MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease
Przedborski, S., Tieu, K., Perier, C., & Vila, M. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041771.66775.d5 · Cited by 287
Interaction Between Chemicals and Melanin
LARSSON, B. S. (1993) · Pigment Cell Research · doi:10.1111/j.1600-0749.1993.tb00591.x · Cited by 287
Crossman, A. R. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90322-8 · Cited by 282
The role of environmental toxins in the etiology of Parkinson's disease
Tanner, C. M. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90135-5 · Cited by 276
Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes
Chiba, K., Trevor, A. J., & Castagnoli, N. (1985) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(85)91071-x · Cited by 269
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis
Banerjee, R., Starkov, A. A., Beal, M. F., & Thomas, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.007 · Cited by 253
Schildknecht, S., Pöltl, D., Nagel, D. M., Matt, F., Scholz, D., Lotharius, J., Schmieg, N., Salvo-Vargas, A., & Leist, M. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.027 · Cited by 115
Martinovits, G., Melamed, E., Cohen, O., Rosenthal, J., & Uzzan, A. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90602-6 · Cited by 67
Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures
Di Monte, D. A., Schipper, H. M., Hetts, S., & Langston, J. W. (1995) · Glia · doi:10.1002/glia.440150213 · Cited by 43
Kulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-230206 · Cited by 40
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Metadata
- Authors
- Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A.
- Venue
- Nature
- Published
- 1984-10
- Volume
- 311
- Issue
- 5985
- Pages
- 464-467
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2041734419
- Cited by
- 786
- References
- 7
- FWCI
- 65.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.